Latest Breaking News On - R pac phase - Page 2 : comparemela.com

RenovoRx Announces $11 1 Million at Market Private Placement

Cash position now expected to fund current operating plan into 2026 Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and.

United statesCompany nasdaqSecurities exchangeNewbridge securities corporationRenovorx incExchange commissionTrans arterial micro perfusionSecurities corporationSeriesb warrantsSeriesb warrantNasdaq stock marketSecurities actDrug evaluationSecurities exchange actR pac phase

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Shaun bagaiCanaccord genuitySecurities exchangeRenovorx incExchange commissionStrategic communicationsCompany nasdaqChief executive officerOncology virtual conferenceBill maughanSenior analystHigh local concentrationsSolid tumorsTrans arterial micro perfusionDrug evaluationSecurities act

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Shaun bagaiJonathan aschoffSecurities exchangeSenior research analyst at rothExchange commissionRitz carltonRenovorx incStrategic communicationsCompany nasdaqChief executive officerDana pointSenior research analystTrans arterial micro perfusionOpportunities conferenceDrug evaluationSecurities act

RenovoRx CEO Issues Letter to Shareholders

Recent financing will drive Company towards second interim analysis on pivotal Phase III TIGeR-PaC clinical trial by end of 2024 .

Shaunr bagaiShaun bagaiData monitoring committeeRenovorx incExchange commissionCompany nasdaqSecurities exchangeChief executive officerFellow renovorx shareholdersTrans arterial micro perfusionOverall survivalCancer research annual meetingLate breaker oral presentationMedical oncology world congressGastrointestinal cancerNew drug application

RenovoRx CEO Issues Letter to Shareholders

RenovoRx, Inc. ("RenovoRx" or the "Company") , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer,.

Shaun bagaiShaunr bagaiSecurities exchangeExchange commissionData monitoring committeeCompany nasdaqRenovorx incChief executive officerFellow renovorx shareholdersTrans arterial micro perfusionOverall survivalCancer research annual meetingLate breaker oral presentationMedical oncology world congressGastrointestinal cancerNew drug application